About us

CoV Biotechnology is an early-stage biotechnology company developing booster vaccines and therapeutics that are effective against variants of SARS-2 beta coronavirus. The booster pan-sarbecovirus vaccine will protect against future variants and future crossovers of related coronaviruses from animals to humans.

Our technology is exclusively licensed from Duke NUS Medical School in Singapore.

Our Science

Broad neutralizing antibodies as therapeutics or passive immunization

We are developing an antibody cocktail which have broad neutralizing activities against sarbecoviruses, which covers both SARS-1 and SARS-2. The antibody cocktail can be used as a therapeutic for people at risk of developing severe COVID-19 disease, and will help ringfence new sarbecovirus outbreaks.


Pan-sarbecovirus vaccination

The coronavirus has been evolving and mutating to escape immunity from current vaccines. We aim to stay ahead of the virus by inducing broad, pan-sarbecovirus immune responses in people that have already received SARS-CoV-2 vaccine or have previously been infected with the SARS-CoV-2 virus.


Monoclonal antibody and vaccine assets in the pipeline

Team

Professor Wang Lin Fa, Scientific Founder & CSO

Prof Wang is the Scientific Founder and Chief Scientific Officer of CoV Biotechnology. He is currently a Professor in the Programme in Emerging Infectious Diseases at Duke-NUS Medical School and the inaugural Executive Director of the Programme for Research in Epidemic Prepardness and Response (PREPARE), Singapore. He is one of the world's leading experts in zoonotic diseases, pathogen discovery and bat immunology, having co-authored more than 500 scientific papers including many top scientific publications in Science, Nature, New England Journal of Medicine and Lancet.

Being internationally recognised as an expert in coronaviruses, Prof Wang has served on multiple committees and advisory boards for various international agencies including World Health Organization (WHO) and Coalition for Epidemic Preparedness Innovation (CEPI) since the start of the COVID-19 pandemic. The recent discovery from his team demonstrate that SARS-1 survivors subsequently receiving COVID-19 mRNA vaccination could produce extremely broad pan-sarbecovirus neutralizing antibodies. This laid the scientific foundation for CoVBio's mission to develop broad spectrum vaccines and therapeutic monoclonal antibodies.


Investors and Partners

Collaboration

CoV Biotechnology is keen to collaborate with partners to develop products against SARS-CoV-2 and other sarbecoviruses.

Monoclonal Antibody

Protein sub-unit Vaccine

mRNA Vaccine

Other modalities (nasal spray, mucosal vaccine)

Contact us

Have questions? We're happy to speak with you. Please feel free to contact us via email and we will get back to you as soon as possible.

Email: info@covbiotech.com

Address: 79 Science Park Drive, Cintech IV, #06-01/08, Singapore 118264